Prime Medicine shares rise 11.21% intraday as CEO to present at Jefferies Global Healthcare Conference.

Prime Medicine surged 11.21% intraday following the announcement that its CEO, Allan Reine, will present at the Jefferies Global Healthcare Conference on November 18, 2025. The event, scheduled during London trading hours, is expected to highlight the company’s progress in developing curative gene-editing therapies using its proprietary Prime Editing platform. The news, combined with a recent analyst upgrade from JonesTrading, which maintained a "Buy" rating with a $5.00 price target, likely fueled investor optimism about the company’s long-term therapeutic pipeline and market potential. The stock’s sharp rise reflects heightened confidence in its ability to advance its gene-editing programs across liver, lung, and oncology indications, aligning with broader sector interest in genetic medicine.